For instance, loss of ARID1A or ARID1B confers enhanced response to immune-checkpoint blockade (ICB) in melanoma and non-small cell lung cancer (13, 14), whereas PBRM1 deficiency promotes primary resistance in renal cell carcinoma (15). This evidence concerns the gene PBRM1 and hereditary clear cell renal cell carcinoma.